SOPHiA GENETICS SA
SOPH- Exchange
- Nasdaq
- Industry
- Services-Computer Processing & Data Preparation
- SEC CIK
- 0001840706
In the last 90 days, SOPHiA GENETICS SA insiders filed 2 open-market purchases and 31 sales; 92 institutions reported holding it in 13F filings for Q3 2026, worth $343.4M in total; Akre Capital Management is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:38 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $79.0M (102.2% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Revenue | $77.3M | $65.2M | $62.4M | $47.6M | $40.5M |
| Cost of revenue | $25.2M | $21.2M | $19.5M | $16.3M | $15.2M |
| Gross profit | $52.1M | $43.9M | $42.9M | $31.3M | $25.2M |
| Operating expenses | – | $131.9M | $138.2M | $135.8M | $112.0M |
| Research and development | $34.2M | $34.4M | $37.0M | $35.4M | $26.6M |
| Selling, general and administrative | $52.6M | $47.0M | $53.3M | $55.8M | $41.5M |
| Operating income | -$70.9M | -$66.6M | -$74.8M | -$87.8M | – |
| Interest expense | $4.55M | $1.91M | $588.0K | $639.0K | $658.0K |
| Income tax | $1.51M | $1.22M | $486.0K | -$136.0K | $168.0K |
| Net income | -$79.0M | -$62.5M | -$79.0M | -$87.4M | -$73.7M |
| EPS, basic | $-1.17 | $-0.95 | $-1.22 | $-1.36 | – |
| EPS, diluted | $-1.17 | $-0.95 | $-1.22 | $-1.36 | – |
| Weighted shares, basic | 67.5M | 66.1M | 64.8M | 64.1M | – |
| Weighted shares, diluted | 67.5M | 66.1M | 64.8M | 64.1M | – |
| Margins and growth | |||||
| Gross margin | 67.4% | 67.4% | 68.8% | 65.7% | 62.4% |
| Operating margin | -91.8% | -102.1% | -120.0% | -184.7% | – |
| Net margin | -102.2% | -95.9% | -126.6% | -183.9% | -182.1% |
| Revenue growth, year over year | +18.6% | +4.5% | +31.1% | +17.6% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Cash and equivalents | $70.3M | $80.2M | $123.3M | $161.3M | $193.0M |
| Accounts receivable | $15.0M | $7.44M | $10.3M | $6.06M | $7.06M |
| Inventory | $6.35M | $5.87M | $6.48M | $5.16M | $5.73M |
| Total current assets | $99.1M | $99.4M | $148.0M | $196.3M | $282.9M |
| Property, plant and equipment | $5.67M | $5.21M | $7.47M | $7.13M | $4.66M |
| Intangible assets | $35.9M | $29.0M | $27.2M | $20.0M | $15.7M |
| Total assets | $163.0M | $155.3M | $206.2M | $243.8M | $320.2M |
| Accounts payable | $8.96M | $5.22M | $5.39M | $6.18M | $6.74M |
| Total current liabilities | $50.5M | $26.8M | $35.6M | $26.8M | $28.6M |
| Long-term debt | $47.7M | $13.2M | – | – | – |
| Total liabilities | $115.9M | $58.8M | $54.7M | $43.7M | $44.8M |
| Shareholders' equity | $47.1M | $96.5M | $151.4M | $200.1M | $275.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Operating cash flow | -$35.9M | -$42.8M | -$48.6M | -$70.1M | -$57.9M |
| Capital expenditures | $574.0K | $244.0K | $1.49M | $4.10M | $2.68M |
| Free cash flow | -$36.5M | -$43.1M | -$50.1M | -$74.2M | -$60.6M |
| Stock-based compensation | $16.2M | $16.5M | $15.2M | $13.6M | $8.51M |
| Investing cash flow | -$8.67M | -$8.18M | $8.32M | $42.0M | -$56.9M |
| Financing cash flow | $30.2M | $11.6M | -$2.82M | -$1.57M | $237.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 21.0% | 25.3% | 24.4% | 28.6% | 21.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.